Screener
Sarepta Therapeutics, Inc. SRPT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Accounts payable | $50,982 | $280,841 |
| Accrued expenses | 325,232 | 359,659 |
| Deferred revenue, current portion | 110,132 | 443,397 |
| Other current liabilities | 16,562 | 11,393 |
| Total current liabilities | 502,908 | 1,095,290 |
| Long-term debt | 847,623 | 828,974 |
| Lease liabilities, net of current portion | 198,226 | 199,378 |
| Deferred revenue, net of current portion | 110,132 | 83,910 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s accrued expenses?
- Sarepta Therapeutics, Inc. (SRPT) reported accrued expenses of $16.56M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Sarepta Therapeutics, Inc.'s accrued expenses increased by 59.0% year-over-year, from $10.42M to $16.56M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s accrued expenses has grown at a -12.4% compound annual growth rate (CAGR), from $22.14M to $11.39M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Sarepta Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude